Top

Published in:

01-10-2020 | Systemic Therapy | Breast Oncology

Primary Site Surgery and Survival Impact in Metastatic HER2-Amplified Breast Cancer: Responsible use of Cohort Data

Authors: Robert W. Krell, MD, Philip M. Spanheimer, MD

Published in: Annals of Surgical Oncology | Issue 10/2020

Excerpt

We read with interest the article by Mudgway et al. entitled “The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy”.1 With significant advances in systemic therapy for human epidermal growth factor receptor 2 (HER2)-amplified breast cancer, the therapeutic advantage of primary site resection in metastatic disease remains an important and open question. …

Mudgway R, Chavez de Paz Villanueva C, Lin AC, Senthil M, Garberoglio CA, Lum SS. The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy. Ann Surg Oncol. 2020;27:2711–2720. https://doi.org/10.1245/s10434-020-08310-2.CrossRefPubMed

National Comprehensive Cancer Network. NCCN guidelines: colon cancer, version 4.2020. 2020. Available at: https://www.nccn.org. Accessed 20 Jun 2020.

Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.CrossRef

Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019;269:1163–9.CrossRef

Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25:3141–9.CrossRef

Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN research group (E2108). J Clin Oncol. 2020;38(18 Suppl):LBA2.

Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018;3:CD011276.

Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269:537–44.CrossRef

Dominici L, Najita J, Hughes M, et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011;129:459–65.CrossRef

10.

Giordano SH, Kuo Y-F, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112:2456–66.CrossRef

11.

Bosco JLF, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64–74.CrossRef

12.

Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–33.CrossRef

13.

Grose E, Wilson S, Barkun J, et al. Use of propensity score methodology in contemporary high-impact surgical literature. J Am Coll Surg. 2020;230:101–12.CrossRef

14.

Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437.e1–e24.CrossRef

15.

Institute of Social and Preventive Medicine. 2009. STROBE Statement: strengthening the reporting of observational studies in epidemiology. Available at: https://www.strobe-statement.org. Accessed 22 Mar 2020.

16.

McMurry TL, Hu Y, Blackstone EH, Kozower BD. Propensity scores: methods, considerations, and applications in the Journal of Thoracic and Cardiovascular Surgery. J Thorac Cardiovasc Surg. 2015;150:14–19.CrossRef

17.

Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109:djw323.

Title: Primary Site Surgery and Survival Impact in Metastatic HER2-Amplified Breast Cancer: Responsible use of Cohort Data
Authors: Robert W. Krell, MD
Philip M. Spanheimer, MD
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Systemic Therapy
Breast Cancer
Breast Cancer
Published in: Annals of Surgical Oncology / Issue 10/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08868-x

2024 ASCO Annual Meeting

Springer Medicine

Primary Site Surgery and Survival Impact in Metastatic HER2-Amplified Breast Cancer: Responsible use of Cohort Data

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2020

Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1–T2cN0 Patients with Positive Sentinel Nodes

Development and External Validation of Radiomics Approach for Nuclear Grading in Clear Cell Renal Cell Carcinoma

Utility of a Second 99mTc-MIBI Scintigraphy Before Reoperation for Patients With Persistent Sporadic Primary Hyperparathyroidism: Results of a Retrospective Multicenter Study

ASO Author Reflections: No Profiling in Male Breast Cancer: Where We are and Where We Should Be

ASO Author Reflections: Quality-of-Life Trajectories After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Warm and Welcoming: Is It What We Say or How We Say It?